Efalizumab Articles
PDL BioPharma swings to profit on cost-cuts
11 May 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Stock Commentary - Europe - week to April 13, 2009
16 April 2009
Another PML case for Genentech's Raptiva
24 November 2008
PML doctor warnings issued for Raptiva
13 October 2008
Raptiva label updated on long-term efficacy
7 July 2008
Strong long-term psoriasis Raptiva data
19 May 2008
Xoma's 2007 loss falls 76% as sales soar 185%
24 March 2008
Xoma posts $22M third quarter profit
19 November 2007
Raptiva impresses in psoriasis study
12 February 2007
Good PASI scores for Serono's Raptiva
6 November 2006
Serono initiates EU-wide Raptiva psoriasis trial
31 July 2006
Serono's net income up 8% in 2nd-qtr
31 July 2006
Xoma reports strong growth in 2005
20 March 2006
Genentech warns on Raptiva risk
1 August 2005
One-time provisional charge blights Serono's 1st-qtr results, putting firm into a loss
22 April 2005
Raptiva effective long-term in psoriasis
28 February 2005
Raptiva launched in UK for psoriasis
8 November 2004
Raptiva available in Germany for psoriasis
11 October 2004
Serono's Raptiva Oked for psoriasis in EU
4 October 2004
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Lehman Bros forecast peak sales of Raptiva at $250M
28 June 2004
Xoma's 1st-qtr 2004 net loss widens 54%
24 May 2004
New data for Serono's Raptiva; CLEAR study
10 May 2004
Serono's 1st-qtr income rockets 76.4%
26 April 2004
Stock Commentary - New York
29 March 2004
Xoma sees net loss jump as revenues fall
22 March 2004
Serono's Raptiva gets first OK in Europe
22 March 2004
Genentech and Protein Design resolve patent dispute
8 December 2003
Serono beats expectations with 3rd-qtr 2003 net income up 48%
3 November 2003
Stock Commentary - Europe
22 September 2003
Xoma plans nine million share offering
22 September 2003
FDA to review Xoma/Genentech's Raptiva
11 August 2003
New data for Xoma/Genentech's Raptiva
4 August 2003
Blow for Genentech and Xoma as drug fails in RA
19 May 2003
Serono
5 May 2003
XOMA and Genentech expand Raptiva collaboration
21 April 2003
Xoma's losses widen ahead of marketing
24 March 2003
Genentech forecasts strong growth
24 March 2003
Stock Commentary - Europe
3 March 2003
Serono files for Raptiva in Europe
3 March 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Serono sees 15%-20% growth for 2003
10 February 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Xoma to start Raptiva trial in psoriatic arthritis
10 February 2003
Monoclonal antibodies on the cusp of strong growth?
10 February 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
Update - Amgen says Enbrel psoriasis trial is positive
27 January 2003
XOMA/Genentech file Raptiva BLA in USA
6 January 2003
Xoma earns $7.5M from Millennium deal
6 January 2003
Xoma/Genentech say Raptiva is long-acting
12 August 2002
Serono and Genentech enters into license agreement
12 August 2002
Genentech 1st-qtr earnings leap
22 April 2002
Stock Commentary - New York
15 April 2002
Enbrel also active in psoriasis, says study
4 March 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
Genentech expects quiet 2002
14 January 2002
Genentech third-qtr revenues jump 24%
16 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
Stock Commentary - New York
11 October 2001
Xanelim delay hits Xoma and partner Genentech, boosts Biogen
8 October 2001
Genentech/Xoma delay US Xanelim submission
5 October 2001
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
